LEADS-B (09887): Updated clinical and translational data for Varisin in the treatment of extrapulmonary neuroendocrine carcinoma, biliary tract cancer, and colorectal cancer presented at the 2026 European Society for Medical Oncology (ESMO) Congress

Zhitong Finance APP News, Leerink-B (09887) announces that updated clinical and translational data from four studies of Vilixin (opamtisumumab, a PD-L1/4-1BB bispecific antibody) were presented at the 2026 European Society for Medical Oncology Congress (2026 ESMO). The presentations include (i) a late-breaking abstract (LBA) oral presentation on Vilixin monotherapy for third-line or later extrapulmonary neuroendocrine carcinoma (EP-NEC); (ii) a preferred oral presentation on Vilixin combined with chemotherapy as first-line treatment for EP-NEC; (iii) a poster presentation on Vilixin combined with chemotherapy as first-line treatment for biliary tract cancer (BTC); and (iv) a translational research poster presentation on Vilixin for microsatellite stable (MSS) colorectal cancer (CRC).